Trials / Completed
CompletedNCT03437590
A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739
An Open-label PET Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Janssen-Cilag International NV · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to measure the blocking of \[18F\]-JNJ-64413739 uptake in the brain at the time to reach maximum plasma concentration (Tmax) and at 24 hours postdose of JNJ-55308942 following a single dose of JNJ-55308942; and to model the exposure/receptor interaction of JNJ-55308942.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-55308942 | JNJ-55308942 will be administered as oral solution. |
| DRUG | [18F]-JNJ-64413739 | \[18F\]-JNJ-64413739 fluid for injection administered intravenously. |
Timeline
- Start date
- 2018-03-15
- Primary completion
- 2018-10-19
- Completion
- 2018-10-19
- First posted
- 2018-02-19
- Last updated
- 2025-04-27
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03437590. Inclusion in this directory is not an endorsement.